SAN DIEGO, September 5, 2013 – ProSciento, Inc., a center of excellence providing early phase diabetes, obesity and cardiometabolic clinical research, is proud to announce that Denon Alderson, manager of recruitment and screening, was awarded Insulindependence’s IN Champion Award, recognizing ProSciento for its corporate support and Denon for her above and beyond commitment to Insulindependence’s cause and to the diabetes patient community.
Insulindependence is a nonprofit outreach organization uniting, expanding, and supporting the active diabetes community through a national membership program and events that teach diabetes self-management through physical activity. Through their outreach success, Insulindependence is considered a leading authority in exercise and recreation for people living with diabetes. The organization’s IN Champion Award honors one corporate individual each year for his or her outstanding passion and support of Insulindependence’s mission and concern for the broader diabetes patient community.
“ProSciento has been a financial supporter of Insulindependence since 2009 and over the past four years, Denon has gone above and beyond her call of duty as a representative of ProSciento. She has wholeheartedly embraced the Insulindependence mission as a volunteer, fundraiser, program participant and dear friend to everyone who is involved with the greater San Diego Diabetes community,” said Peter H. Nerothin, Insulindependence’s Founder and President. “Denon’s passion for improving the lives of patients is truly remarkable.”
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
For business development inquires:
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427